Abatacept, in combination with standard prophylaxis treatments, is being developed for the
prophylaxis of acute graft versus host disease (aGvHD) in unrelated-donor hematopoietic stem
cell transplantation (HSCT). GvHD is characterised as a frequent complication of bone marrow
transplantation and involves a reaction between the donor cells and the recipient's native tissues,
leading to injury of the recipient's tissues. GvHD occurs in acute and chronic form. The organs
most affected in aGvHD are the stomach, intestines, skin, and liver. Between 30-55% of patients
with a HSCT go on to develop aGvHD and with no approved prophylaxis treatment options, there
is significant unmet need.
Abatacept with a calcineurin inhibitor and methotrexate for prophylaxis of acute graft versus host disease
Abatacept, in combination with standard prophylaxis treatments, is being developed for the prophylaxis of acute graft versus host disease (aGvHD) in unrelated-donor hematopoietic stem cell transplantation (HSCT). GvHD is characterised as a frequent complication of bone marrow transplantation and involves a reaction between the donor cells and the recipient's native tissues, leading to injury of the recipient's tissues.
Interventions:
Abatacept (Orencia)
Indications:
Graft versus host disease (GvHD)
Therapeutic Areas:
Immunology
Year:
2022